MétaCan
Menu
← Retour à la cohorte
Enregistrement W4389231016 · doi:10.1182/blood-2023-172922

Oral Anticoagulant (OAC) Use Among Medicare Patients Newly Diagnosed with Venous Thromboembolism (VTE): Factors Associated with Treatment Status

2023· article· en· W4389231016 sur OpenAlexaff
James C. Coons, Aolin Wang, Dominick Latrémouille-Viau, Cristina Russ, Dong Cheng, Robert Stellhorn, Feng Dai, David R. Steffen, Abigail Zion, Serina Deeba, Dionne M. Hines

Notice bibliographique

RevueBlood · 2023
Typearticle
Langueen
DomaineMedicine
ThématiqueVenous Thromboembolism Diagnosis and Management
Établissements canadiensGroup for Research in Decision Analysis
Organismes subventionnairesnon disponible
Mots-clésMedicineApixabanRivaroxabanEdoxabanWarfarinDabigatranInternal medicineAmbulatoryAtrial fibrillationVenous thromboembolismCohortEmergency medicineThrombosis

Résumé

récupéré en direct d'OpenAlex

Introduction Clinical guidelines recommend initial treatment with OACs, such as direct-acting oral anticoagulants (DOACs; apixaban, dabigatran, edoxaban, rivaroxaban) or warfarin, for at least 3 months after an initial venous thromboembolism (VTE) event. Early OAC use is associated with improved clinical outcomes and helps prevent VTE recurrence. Purpose To estimate the proportion of Medicare beneficiaries newly diagnosed with VTE with and without OAC treatment within the month from first VTE and identify factors associated with being untreated in that period. Additionally, to identify factors associated with treatment with DOACs or warfarin among OAC-treated patients. Methods Data from 1/1/2014-12/31/2019 of Medicare beneficiaries aged ≥65 years with a new diagnosis of VTE in the inpatient or ambulatory (including emergency room [ER]) setting from 1/1/2015 to 12/31/2019 were included. Additional eligibility criteria included continuous Medicare Parts A, B and D enrollment ≥12 months before and ≥30 days after first VTE diagnosis (index VTE), no diagnosis for atrial fibrillation, inferior vena cava filter, pregnancy or cancer, and no OAC treatment prior to index VTE. VTE patients with ≥1 outpatient pharmacy claims for a DOAC or warfarin within 30 days from index VTE were considered OAC-treated; otherwise, they were classified as untreated. Patients in the OAC-treated cohort were further classified into the DOAC or warfarin subgroups based on the first OAC treatment observed from index VTE (index OAC). Factors associated with being untreated with OACs (vs. treated) and with receiving treatment with DOACs (vs. warfarin) were assessed using multivariable logistic regressions. Results A total of 169,928 patients (49.7% OAC-treated; 50.3% untreated) were identified. In the OAC-treated cohort, 62,528 (74.0%) had DOACs (mainly apixaban [51.9%] and rivaroxaban [46.9%]), and 29,324 (26.0%) warfarin as index OAC. Within the OAC-treated and untreated cohorts respectively, mean age was 76.2 and 77.3 years, 62.9% and 66.4% were female, 82.6% and 75.4% were Non-Hispanic White, mean CCI score was 2.0 and 3.0, 51.8% and 70.3% had DVT only, and 48.2% and 29.7% had PE. Factors associated with being untreated with OACs (odds ratio; 95% confidence interval) included Hispanic ethnicity (vs. White) (1.35; 1.29-1.42), congestive heart failure (1.44; 1.39-1.48), cerebrovascular disease (1.36; 1.32-1.39), anemia (1.25; 1.22-1.28), and peripheral vascular disease (1.22; 1.19-1.25). Having part D low-income subsidy was also associated with being untreated with OACs (1.14; 1.07, 1.20). Index VTE diagnosis setting being ER (vs. outpatient) (0.38; 0.36-0.39) and pulmonary embolism (vs. DVT) (0.45; 0.44-0.46) were associated with increased odds of being treated with OAC, as was being diagnosed by a radiologist (0.62; 0.60-0.64), emergency medicine physician (0.52; 0.49-0.56) or hematologist (0.56; 0.50-0.63) (vs. primary care) ( Figure 1). Among the OAC-treated cohort, factors associated with being treated with DOACs vs. warfarin included diagnosis in more recent years, VTE in ER setting (1.22; 1.15-1.30). VTE in inpatient setting (0.74; 0.70-0.78) and renal disease (0.73; 0.70-0.76) were associated with increased odds of being treated with warfarin, as were Northeast (0.79; 0.76-0.83), Midwest (0.52; 0.50-0.54), and West US census regions (0.56; 0.53-0.59), respectively ( Figure 2). Conclusions In this study of Medicare patients, nearly half of the patients with ICD codes for VTE were not treated with OAC in the first month from initial diagnosis. Among OAC-treated patients, a higher proportion of patients were treated with DOAC vs. warfarin, consistent with more recent guideline recommendation. Factors associated with being untreated might reflect challenges associated with VTE management among disadvantaged populations and in the presence of certain comorbidities.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,003
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,022
Score d'incertitude au seuil0,044

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0000,003
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,001
Bibliométrie0,0020,002
Études des sciences et des technologies0,0010,000
Communication savante0,0010,001
Science ouverte0,0010,001
Intégrité de la recherche0,0010,001
Charge utile insuffisante (le modèle a refusé de juger)0,0030,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,031
Tête enseignante GPT0,254
Écart entre enseignants0,222 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations1
Publié2023
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBlood→Même sujetVenous Thromboembolism Diagnosis and Management→Travaux en français237 207→